INOZYME
Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.
INOZYME
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2016-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.inozyme.com
Total Employee:
11+
Status:
Active
Contact:
+1 (857) 330-4340
Email Addresses:
[email protected]
Total Funding:
220.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
NeoGenomics
NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
ZS Pharma
ZS Pharma develops ion trap therapies for the treatment of life-threatening medical conditions such as hyperkalemia and liver diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
K2 HealthVentures
K2 HealthVentures investment in Post-IPO Debt - Inozyme
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series A - Inozyme
RA Capital Management
RA Capital Management investment in Series A - Inozyme
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series A - Inozyme
Sofinnova Investments
Sofinnova Investments investment in Series A - Inozyme
Sanofi Ventures
Sanofi Ventures investment in Series A - Inozyme
New Enterprise Associates
New Enterprise Associates investment in Series A - Inozyme
Rock Springs Capital
Rock Springs Capital investment in Series A - Inozyme
Longitude Capital
Longitude Capital investment in Series A - Inozyme
Novo Holdings
Novo Holdings investment in Series A - Inozyme
Key Employee Changes
Official Site Inspections
http://www.inozyme.com Semrush global rank: 4.29 M Semrush visits lastest month: 2.68 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Inozyme"
Inozyme - Crunchbase Company Profile & Funding
Organization. Inozyme . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Inozyme is a provider of therapies for rare …See details»
Inozyme Org Chart + Executive Team - The Official Board
Organizational Chart of Inozyme. Inozyme Org Chart www.inozyme.com. has 17 executives +1 857 330 4340; Add an executive. Latest news on Inozyme (INZY) Anything missing? We …See details»
Inozyme Pharma - LinkedIn
Inozyme Pharma | 7,606 followers on LinkedIn. We are a pioneering, clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases …See details»
Governance - Inozyme Pharma, Inc.
The Investor Relations website contains information about Inozyme Pharma, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Inozyme Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Inozyme is a biopharmaceutical company specializing in the developing of novel therapeutics to treat rare metabolic diseases. The Company's area of expertise is disorders of …See details»
Inozyme - businessabc
Feb 25, 2025 Inozyme has been the recipient of numerous awards and recognitions. These include the 2019 Biotechnology Innovation Organization Emerging Company of the Year, the …See details»
Inozyme Pharma - VentureRadar
Inozyme Pharma is a biotechnology company committed to developing novel medicines for the treatment of rare mineralization disorders. Inozyme Pharma was founded in 2017 by Joseph …See details»
Inozyme Pharma - Work in biotech
Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapies for patients with rare mineralization disorders. The company's unique science is based on its proprietary …See details»
Inozyme Pharma - Overview, News & Similar companies - ZoomInfo
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the …See details»
Inozyme Pharma, Inc. (INZY): history, ownership, mission, how it …
Ever heard of a biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases? That's Inozyme Pharma, Inc. (INZY). But how exactly does this company …See details»
Working at Inozyme Pharma Inc - Great Place To Work®
88% of employees at Inozyme Pharma Inc say it is a great place to work . ... Today, our Trust Model™ offers an unmatched opportunity to identify what’s happening within your organization. Great Place To Work’s survey and …See details»
Senior Leadership - Inozyme
We are dedicated to restoring health and hope to patients with rare diseases. Our deep understanding of the PPi-Adenosine Pathway drives our mission to develop innovative …See details»
About - Inozyme
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you …See details»
Inozyme plans $75m IPO as it heads for clinic with rare …
6 days ago US biotech Inozyme Pharma is the latest to jump on to the IPO bandwagon, setting terms for a $75 million stock market launch, as the firm gears up for clinical trials of its lead drug for rare ...See details»
Inozyme Pharma Reports Full Year 2022 Financial Results and
Mar 22, 2023 Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases …See details»
Inozyme - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Inozyme . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 12. Number of Board …See details»
BioCentury - Treco to succeed Bolte as CEO of Inozyme
Mar 23, 2023 Inozyme Pharma Inc. (NASDAQ:INZY) n am ed Chair Douglas Treco to succeed CEO Axel Bolte, effective April 1. Treco was co-founder, president and CEO of Ra …See details»
A rare disease veteran, Inozyme’s new CEO sharpens the
Jul 11, 2023 Welcome to First 90 Days, a series dedicated to examining how biopharma executives are planning for success in their new role. Today, we’re looking at Inozyme’s new …See details»
BioMarin Strengthens Enzyme Therapy Business with Acquisition …
1 day ago SAN RAFAEL, Calif. and BOSTON, May 16, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Inozyme Pharma, Inc. (Nasdaq: INZY) announced …See details»
Inozyme Pharma Reports Full Year 2024 Financial Results
Mar 10, 2025 Inozyme Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of …See details»